Vigil Neuroscience (VIGL) Competitors $8.05 0.00 (0.00%) As of 08/5/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VIGL vs. NVTS, AUPH, BHVN, SDGR, EWTX, EVO, ABCL, JANX, ARDX, and WVEShould you be buying Vigil Neuroscience stock or one of its competitors? The main competitors of Vigil Neuroscience include Navitas Semiconductor (NVTS), Aurinia Pharmaceuticals (AUPH), Biohaven (BHVN), Schrodinger (SDGR), Edgewise Therapeutics (EWTX), Evotec (EVO), AbCellera Biologics (ABCL), Janux Therapeutics (JANX), Ardelyx (ARDX), and WAVE Life Sciences (WVE). Vigil Neuroscience vs. Its Competitors Navitas Semiconductor Aurinia Pharmaceuticals Biohaven Schrodinger Edgewise Therapeutics Evotec AbCellera Biologics Janux Therapeutics Ardelyx WAVE Life Sciences Navitas Semiconductor (NASDAQ:NVTS) and Vigil Neuroscience (NASDAQ:VIGL) are related small-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings. Do insiders & institutionals hold more shares of NVTS or VIGL? 46.1% of Navitas Semiconductor shares are owned by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are owned by institutional investors. 29.9% of Navitas Semiconductor shares are owned by insiders. Comparatively, 18.0% of Vigil Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger valuation and earnings, NVTS or VIGL? Vigil Neuroscience has lower revenue, but higher earnings than Navitas Semiconductor. Navitas Semiconductor is trading at a lower price-to-earnings ratio than Vigil Neuroscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavitas Semiconductor$83.30M17.20-$84.60M-$0.65-10.35Vigil NeuroscienceN/AN/A-$84.26M-$2.05-3.93 Do analysts prefer NVTS or VIGL? Navitas Semiconductor currently has a consensus target price of $5.65, suggesting a potential downside of 15.99%. Vigil Neuroscience has a consensus target price of $10.80, suggesting a potential upside of 34.16%. Given Vigil Neuroscience's higher probable upside, analysts plainly believe Vigil Neuroscience is more favorable than Navitas Semiconductor.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Navitas Semiconductor 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29Vigil Neuroscience 0 Sell rating(s) 10 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is NVTS or VIGL more profitable? Vigil Neuroscience has a net margin of 0.00% compared to Navitas Semiconductor's net margin of -182.63%. Navitas Semiconductor's return on equity of -18.16% beat Vigil Neuroscience's return on equity.Company Net Margins Return on Equity Return on Assets Navitas Semiconductor-182.63% -18.16% -16.26% Vigil Neuroscience N/A -111.70%-74.67% Which has more risk & volatility, NVTS or VIGL? Navitas Semiconductor has a beta of 3.02, indicating that its stock price is 202% more volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 3.33, indicating that its stock price is 233% more volatile than the S&P 500. Does the media favor NVTS or VIGL? In the previous week, Navitas Semiconductor had 7 more articles in the media than Vigil Neuroscience. MarketBeat recorded 9 mentions for Navitas Semiconductor and 2 mentions for Vigil Neuroscience. Vigil Neuroscience's average media sentiment score of 1.21 beat Navitas Semiconductor's score of 0.80 indicating that Vigil Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Navitas Semiconductor 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vigil Neuroscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNavitas Semiconductor beats Vigil Neuroscience on 8 of the 15 factors compared between the two stocks. Get Vigil Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIGL vs. The Competition Export to ExcelMetricVigil NeuroscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$383.91M$3.13B$5.71B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-3.9320.9230.9125.28Price / SalesN/A232.70404.2188.50Price / CashN/A41.5625.2228.45Price / Book4.609.779.536.01Net Income-$84.26M-$54.74M$3.26B$265.34M7 Day PerformanceN/A8.37%4.66%2.89%1 Month Performance-0.25%7.94%5.35%1.61%1 Year Performance130.66%18.27%32.14%25.61% Vigil Neuroscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIGLVigil Neuroscience3.339 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340Positive NewsNVTSNavitas Semiconductor2.7998 of 5 stars$6.60-0.9%$5.65-14.4%+123.2%$1.27B$68.17M-10.15160Analyst DowngradeAUPHAurinia Pharmaceuticals2.6383 of 5 stars$11.43+0.5%$12.00+5.0%+96.0%$1.50B$235.13M26.58300Positive NewsBHVNBiohaven3.7867 of 5 stars$13.42-8.9%$58.46+335.5%-59.3%$1.37BN/A-1.43239Earnings ReportAnalyst RevisionSDGRSchrodinger3.1863 of 5 stars$18.63-3.0%$32.75+75.8%-1.8%$1.37B$207.54M-7.51790News CoverageAnalyst DowngradeEWTXEdgewise Therapeutics2.2843 of 5 stars$12.99+2.4%$40.64+212.8%-23.3%$1.37BN/A-8.3860Gap UpEVOEvotec1.7764 of 5 stars$3.81-3.1%$5.90+54.9%+15.3%$1.35B$862.40M0.004,827Analyst RevisionABCLAbCellera Biologics2.278 of 5 stars$4.50+5.9%$8.00+77.8%+75.9%$1.34B$28.83M-8.18500Analyst UpgradeGap UpJANXJanux Therapeutics2.7129 of 5 stars$22.67-0.7%$91.89+305.3%-39.2%$1.34B$9.34M-12.5930ARDXArdelyx4.3443 of 5 stars$5.40+3.6%$11.50+113.0%+2.1%$1.30B$333.61M-23.4890WVEWAVE Life Sciences4.7361 of 5 stars$8.10+0.1%$20.27+150.2%+71.8%$1.29B$108.30M-9.00240 Related Companies and Tools Related Companies NVTS Competitors AUPH Competitors BHVN Competitors SDGR Competitors EWTX Competitors EVO Competitors ABCL Competitors JANX Competitors ARDX Competitors WVE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIGL) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vigil Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.